

6. Part F.II(a), Section 2692(a) of the PHS Act—AIDS Education and Training Centers (AETC);

7. Part F.II.(b), Section 2692(b) of the PHS Act—Dental Schools Reimbursement Program.

This delegation supersedes the delegation memorandum from the Assistant Secretary for Health to the HRSA Administrator, dated May 24, 1991.

This delegation is effective upon date of signature. In addition, I hereby affirm and ratify any actions taken by the HRSA Administrator or any subordinates which, in effect, involved the exercise of the authorities delegated herein prior to the effective date of the delegation.

Dated: January 20, 1998.

**Donna E. Shalala,**  
Secretary.

[FR Doc. 98-2040 Filed 1-27-98; 8:45 am]  
BILLING CODE 4160-15-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Advisory Committee on Immunization Practices: Meeting**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

*Name:* Advisory Committee on Immunization Practices (ACIP).

*Times and Dates:* 8:30 a.m.–5:15 p.m., February 11, 1998; 8:30 a.m.–1:15 p.m., February 12, 1998.

*Place:* CDC, Auditorium B, Building 2, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

*Status:* Open to the public, limited only by the space available.

*Purpose:* The Committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate,

revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.

*Matters To Be Discussed:* Agenda items will include updates from the National Center for Infectious Diseases; the National Immunization Program; the Vaccine Injury Compensation Program; the National Vaccine Program; update on influenza A(H5N1): epidemiologic and virologic surveillance and present status of vaccine development; update on influenza surveillance—U.S. and worldwide; influenza vaccination and Guillain Barre syndrome: update and proposed changes to ACIP recommendations; proposed changes to the 1998–1999 ACIP recommendations for prevention and control of influenza; immunization of bone marrow transplant recipients recommendations on the use of Rotashield® (rotavirus vaccine) as part of the routine childhood immunization schedule; report of work group on computerization of ACIP recommendations; ACIP combination vaccines recommendation; comprehensive resolutions for the Vaccines for Children (VFC) Program; vaccine identification standards initiative; and alopecia associated with hepatitis B vaccination. Other matters of relevance among the committee's objectives may be discussed.

Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Gloria A. Kovach, Committee Management Specialist, CDC, 1600 Clifton Road, NE, M/S'D-50, Atlanta, Georgia 30333, telephone 404/639-7250.

Dated: January 21, 1998.

**Carolyn J. Russell,**

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98-1998 Filed 1-27-98; 8:45 am]  
BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**Advisory Committees; Notice of Meetings**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory committees for 1998. At the request of the Commissioner of Food and Drugs (the Commissioner), the Institute of Medicine (the IOM) conducted a study of the use of FDA's advisory committees. The IOM recommended that the agency publish an annual tentative schedule of its meetings in the **Federal Register**. In response to that recommendation, FDA is publishing its annual tentative schedule of meetings for 1998.

**FOR FURTHER INFORMATION CONTACT:** Donna M. Combs, Committee Management Office (HFA-306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4820.

**SUPPLEMENTARY INFORMATION:** The IOM, at the request of the Commissioner, undertook a study of the use of FDA's advisory committees. In its final report, the IOM recommended that FDA adopt a policy of publishing an advance yearly schedule of its upcoming public advisory committee meetings in the **Federal Register**. FDA has implemented this recommendation. A tentative schedule of forthcoming meetings will be published annually in the **Federal Register**. The annual publication of tentatively scheduled advisory committee meetings will provide both advisory committee members and the public with the opportunity, in advance, to schedule attendance at FDA's upcoming advisory committee meetings. The schedule is tentative and amendments to this notice will not be published in the **Federal Register**. FDA will publish a **Federal Register** notice at least 15 days in advance of each upcoming advisory committee meeting, announcing the meeting (21 CFR 14.20).

The following list announces FDA's tentatively scheduled advisory committee meetings for 1998:

Committee Name	Dates of Meetings	Information-Line Code
OFFICE OF THE COMMISSIONER		
Science Board to the Food and Drug Administration	May 19 ..... September 15	12603
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH		
Allergenic Products Advisory Committee	March 23–24 ..... September 14–15	12388
Biological Response Modifiers Advisory Committee	March 23–24 .....	12389